Insider Buying: Fractyl Health (NASDAQ:GUTS) Director Acquires 23,000 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ajay Royan acquired 23,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average cost of $0.85 per share, for a total transaction of $19,550.00. Following the transaction, the director owned 40,901 shares of the company’s stock, valued at approximately $34,765.85. This represents a 128.48% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Fractyl Health Price Performance

GUTS stock remained flat at $0.85 during trading hours on Monday. 1,732,242 shares of the company’s stock traded hands, compared to its average volume of 3,947,680. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The stock has a market cap of $134.85 million, a P/E ratio of -0.66 and a beta of 2.34. Fractyl Health, Inc. has a 12 month low of $0.38 and a 12 month high of $2.45. The stock has a 50 day moving average of $0.70 and a 200 day moving average of $1.06.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.23. Sell-side analysts expect that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds and other institutional investors have recently made changes to their positions in GUTS. Nantahala Capital Management LLC acquired a new position in shares of Fractyl Health during the 3rd quarter worth about $19,298,000. Alyeska Investment Group L.P. bought a new position in Fractyl Health in the 3rd quarter worth approximately $8,981,000. Rosalind Advisors Inc. bought a new position in Fractyl Health in the 3rd quarter worth approximately $7,950,000. Woodline Partners LP lifted its holdings in shares of Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after buying an additional 4,908,693 shares during the last quarter. Finally, General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health in the second quarter valued at approximately $7,912,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GUTS. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.